top of page

11  /  01  /  2022

Biased holoenzyme assembly of Protein Phosphatase 2A (PP2A): from cancer to small molecules

12  /  17  /  2021

Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma

07  /  16  /  2021

Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents

10  /  07  /  2020

The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies

04  /  20  /  2020

Selective PP2A Enhancement through Biased Heterotrimer Stabilization

12  /  10  /  2019

Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers

09  /  27  /  2019

Protein phosphatase 2A controls ongoing DNA replication by binding to and regulating cell division cycle 45 (CDC45)

09  /  20  /  2019

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

05  /  29  /  2019

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

07  /  17  /  2018

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

04  /  01  /  2018

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

10  /  08  /  2017

Therapeutic targeting of PP2A

05  /  15  /  2017

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

10  /  28  /  2015

All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase

12  /  16  /  2014

Repurposing of bisphosphonates for the prevention and therapy of non-small cell lung and breast cancer

11  /  11  /  2014

Bisphosphonates inactivate human EGFRs to exert anti-tumor actions

01  /  07  /  2014

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition

01  /  23  /  2013

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival

06  /  01  /  2012

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response

07  /  01  /  2005

Targeted inhibition of the KLF6 splice variant KLF6SV1 suppresses prostate cancer growth and spread

02  /  01  /  2005

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk

12  /  21  /  2001

KLF6, a candidate tumor suppressor gene in prostate cancer

04  /  01  /  1995

The apolipoprotein(a) gene is regulated by sex hormones and acute phase inducers in YAC transgenic mice
Read all published papers from the Narla Lab here.
BE IN 
TOUCH

University of Michigan Medical Center
1500 E. Medical Center Drive

Rogel Cancer Center 3110, 3120, 3130, 3131 

Ann Arbor, MI 48109

Lab Phone:  (734) 763 - 4010

© 2024

Rogel-Informal-white.png
bottom of page